Sign in
Taking people in United StatesPhase 2

Tests alendronate for bone death in adults with sickle cell disease

Tests alendronate, a pill, in adults with sickle cell disease and bone damage.

Key facts

Who runs it
University of California, Davis
Where
Sacramento, United StatesSee the site
Trial code
Registry title
Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
Status
Recruiting
Phase
Phase 2
People taking part
30 people, planned
Started
9 Mar 2026
Expected to end
Dec 2027
Type of study
Interventional
Treatments tested
  • Alendronate Sodium
Record updated
16 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with sickle cell disease and osteonecrosis (bone damage from poor blood supply) to take alendronate tablets.

Age
18 to 80 years
Sex
All sexes can join.
Disease stage
Sickle cell disease of any genotype, confirmed by hemoglobin electrophoresis or high performance liquid chromatography, with osteonecrosis.

Main reasons for not taking part

  • Pregnant women
  • Adults unable to consent
  • Prisoners
  • Hospital stay for any cause within 2 weeks of study entry
  • Anyone who cannot lie on a DXA scanner

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Age 18-80 years with SCD (any genotype, confirmed by hemoglobin electrophoresis or high performance liquid chromatography)
  • Ability to provide written informed consent
  • Ability to lay on a dual-energy X-ray absorptiometry (DXA) scanner
  • Negative urine pregnancy test for anyone of childbearing potential at study entry

Who cannot take part

  • Pregnant women
  • Adults unable to consent
  • Individuals who are not yet adults (infants, children, teenagers)
  • Prisoners
  • Hospitalizations (for any cause) within 2 weeks of study entry

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

This trial is currently available in United States.

  • UC Davis Comprehensive Cancer CenterSacramento, United StatesContact: Leyla Y Teos, PhDTaking people

About the trial

What the trial wants to find out

A prospective, single-arm, intervention study of oral alendronate in adults with sickle cell disease and osteonecrosis

The group in the trial

  • Alendronate groupTreatment being tested

    Single-arm prospective cohort of 30 adult with SCD

    Treatment: Alendronate Sodium

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Feasibility Study of Alendronate as Treatment for Osteonecrosis in Adults With Sickle Cell Disease
Plain-language title
Tests alendronate for bone death in adults with sickle cell diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT06016634, who can take part
Record updated
16 July 2026